Analyst Reco. Amicus Therapeutics, Inc.

Equities

FOLD

US03152W1099

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-29 EDT			5-day change	1st Jan Change
10.25 ^USD	-0.29%		-5.27%	-27.77%

03-18	JPMorgan Adjusts Price Target on Amicus Therapeutics to $19 From $21, Maintains Overweight Rating	MT
03-05	Amicus Therapeutics Insider Sold Shares Worth $389,543, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Adjusts Price Target on Amicus Therapeutics to $19 From $21, Maintains Overweight Rating	03-18	MT
Morgan Stanley Upgrades Amicus Therapeutics to Overweight From Equalweight, Raises Price Target to $20 From $15	12-19	MT
Morgan Stanley Adjusts Price Target on Amicus Therapeutics to $15 From $14, Maintains Equalweight Rating	11-09	MT
Morgan Stanley Trims Amicus Therapeutics' Price Target to $14 From $15, Keeps Equalweight Rating	23-10-10	MT
UBS Ups Price Target on Amicus Therapeutics to $20 From $19, Maintains Buy Rating	23-09-29	MT
JPMorgan Raises Price Target on Amicus Therapeutics to $19 From $17, Maintains Overweight Rating	23-09-29	MT
UBS Adjusts Amicus Therapeutics Price Target to $19 From $17, Maintains Buy Rating	23-08-09	MT
BofA Securities Adjusts Price Target on Amicus Therapeutics to $17 From $16, Maintains Buy Rating	23-03-28	MT
Goldman Sachs Adjusts Amicus Therapeutics' Price Target to $11 From $10, Keeps Neutral Rating	23-03-02	MT
UBS Adjusts Amicus Therapeutics Price Target to $17 From $15, Maintains Buy Rating	23-03-02	MT
BTIG Adjusts Price Target on Amicus Therapeutics to $16 From $14, Maintains Buy Rating	23-01-18	MT
Morgan Stanley Adjusts Price Target on Amicus Therapeutics to $15 From $14, Maintains Equalweight Rating	22-11-08	MT
Berenberg Bank Adjusts Amicus Therapeutics Price Target to $12 From $11 on Improved Confidence in AT-GAA, Maintains Hold Rating	22-11-01	MT
Morgan Stanley Initiates Amicus Therapeutics at Equalweight Rating With $14 Price Target	22-09-09	MT
Goldman Sachs Reinstates Amicus Therapeutics at Neutral With $11 Price Target	22-04-13	MT
Berenberg Bank Adjusts Amicus Therapeutics' Price Target to $12 From $14, Maintain Hold Rating	22-02-25	MT
SVB Leerink Upgrades Amicus Therapeutics to Outperform From Market Perform; Price Target is $16	22-01-14	MT
Cantor Fitzgerald Adjusts Amicus Therapeutics' Price Target to $15 from $16, Keeps Overweight Rating	22-01-13	MT
Stifel Lifts Amicus Therapeutics to Buy From Hold, Price Target to $16 From $12	21-11-15	MT
ANALYSTS' OPINIONS OF THE DAY : Admiral, Dollar Tree, EasyJet, Netflix, Planet Fitness...	21-11-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Amicus Therapeutics, Inc.

Equities

FOLD

US03152W1099

Analyst Reco.

Filters